ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CAH Cardinal Health Inc

98.46
0.00 (0.00%)
Pre Market
Last Updated: 09:01:27
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cardinal Health Inc NYSE:CAH NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 98.46 0 09:01:27

Bob Azelby to join Cardinal Health Board of Directors

28/02/2024 9:15pm

PR Newswire (US)


Cardinal Health (NYSE:CAH)
Historical Stock Chart


From Feb 2024 to May 2024

Click Here for more Cardinal Health Charts.

DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.

Cardinal Health Logo (PRNewsfoto/Cardinal Health)

Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmaceuticals. Before joining Alder BioPharmaceuticals, Mr. Azelby was the Chief Commercial Officer of Juno Therapeutics, and served 15 years in a variety of commercial roles at Amgen.

Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics. He also formerly served on the Boards of Directors for Chinook Therapeutics, Eliem Therapeutics, Clovis Oncology, Immunomedics, Alder BioPharmaceuticals, and Cascadian Therapeutics.

"Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health. "Bob's vast experience and expertise within the specialty pharmaceutical arena will add great value to our company and we're pleased to welcome him to our board."

"Bob brings to our board more than three decades of experience and high performance across a multitude of healthcare industries, including oncology and other specialty areas, which I believe will make him a uniquely valuable addition," said Jason Hollar, CEO of Cardinal Health. "We look forward to tapping into Bob's extensive expertise as we continue the momentum against our strategic priorities."    

Mr. Azelby holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Contacts
Media: Erich Timmerman, erich.timmerman@cardinalhealth.com and 614.757.8231
Investors: Matt Sims, matt.sims@cardinalhealth.com and 614.553.3661

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bob-azelby-to-join-cardinal-health-board-of-directors-302074485.html

SOURCE Cardinal Health

Copyright 2024 PR Newswire

1 Year Cardinal Health Chart

1 Year Cardinal Health Chart

1 Month Cardinal Health Chart

1 Month Cardinal Health Chart

Your Recent History

Delayed Upgrade Clock